Metabolism of bradykinin in aorta of hypertensive rats

• Autorzy: Bujak-Gizycka B. , Olszanecki R. , Madej J. , Suski M. , Gebska A. , Korbut R.
• Języki publikacji: EN

Abstrakty

EN

 Alterations in the formation and metabolism of bradykinin (Bk) are hypothesized to play a role in the pathophysiology of hypertension, atherosclerosis and vascular complications of diabetes. However, despite its prominent role in cardiovascular regulation, studies on bradykinin have been limited by various difficulties in accurate measurements of this peptide in biological samples. In this study, using the LC-ESI-MS method we estimated the conversion of exogenous Bk to its main metabolites - Bk-(1-5) and Bk-(1-7) - in endothelial cell culture and in fragments of aorta of normotensive (WKY) and hypertensive rats (SHR). The effects of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitors were more pronounced in SHR: perindoprilat inhibited Bk-(1-5) formation by 49 % and 76 % in WKY and SHR rats, respectively, and tiorphan tended to decrease formation of Bk-(1-5) in both groups of animals. The degradation of bradykinin and generation of both metabolites were significantly higher in the aorta of SHR rats than in WKY controls. Our results show that even in relatively early hypertension (in 4-month old SHR rats) inactivation of Bk by aorta wall is enhanced.

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2011
• Tom: 58
• Numer: 2
• Opis fizyczny: p.199-202,fig.,ref.

Twórcy

autor

Bujak-Gizycka B.

• Chair of Pharmacology, Jagiellonian University Medical College, Krakow, Poland

autor

Olszanecki R.

autor

Madej J.

autor

Suski M.

autor

Gebska A.

autor

Korbut R.

Bibliografia

• Balyasnikova IV, Danilov SM, Muzykantov VR, Fisher AB (1998) Modulation of angiotensin-converting enzyme in cultured human vascular endothelial cells. In Vitro Cell Dev Biol Anim 34: 545-554. 
• Baudin B, Berard M, Carrier JL, Legrand Y, Drouet L (1997) Vascular origin determines angiotensin I-converting enzyme expression in endothelial cells. Endothelium 5: 73-84. 
• Bernatova I, Conde MV, Kopincova J, Gonzalez MC, Puzserova A, Arribas SM (2009) Endothelial dysfunction in spontaneously hypertensive rats: focus on methodological aspects. J Hypertens Suppl 27: S27-S31. 
• Bryant JW, Shariat-Madar Z (2009) Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem 7: 234-250. 
• Bujak-Gizycka B, Madej J, Wolkow PP, Olszanecki R, Drabik L, Rutowski J, Korbut R (2007) Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography - electrospray ionization - mass spectrometry (LC-ESI-MS). J Physiol Pharmacol 58: 529-540. 
• Campbell DJ, Kladis A, Duncan AM (1993) Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21: 155-165. 
• Campbell DJ, Duncan AM, Kladis A, Harrap SB (1995) Increased levels of bradykinin and its metabolites in tissues of young spontaneously hypertensive rats. J Hypertens 13: 739-746. 
• D'Agostino PA, Hancock JR, Provost LR (1997) Analysis of bioactive peptides by liquid chromatography-high-resolution electrospray mass spectrometry. J Chromatogr A 767: 77-85. 
• Dendorfer A, Wolfrum S, Wagemann M, Qadri F, Dominiak P (2001) Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 280: H2182-H2188. 
• Edgell CJ, Haizlip JE, Bagnell CR, Packenham JP, Harrison P, Wilbourn B, Madden VJ (1990) Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926. In Vitro Cell Dev Biol 26: 1167-1172. 
• Erdos EG, Marcic BM (2001) Kinins, receptors, kininases and inhibitors - where did they lead us? Biol Chem 382: 43-47. 
• Erdos EG, Deddish PA (2002) The kinin system: suggestions to broaden some prevailing concepts. Int Immunopharmacol 2: 1741-1746. 
• Ferreira SH, Vane JR (1967) Half-lives of peptides and amines in the circulation. Nature 215: 1237-1240. 
• Gryglewski RJ, Uracz W, Chlopicki S, Marcinkiewicz E (2002) Bradykinin as a major endogenous regulator of endothelial function. Pediatr Pathol Mol Med 21: 279-290. 
• Hasan AA, Amenta S, Schmaier AH (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94: 517-528. 
• Hasan AA, Rebello SS, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi BR, Schmaier AH (1999) Thrombostatin inhibits induced canine coronary thrombosis. Thromb Haemost 82: 1182-1187. 
• Marshall P, Heudi O, McKeown S, Amour A, Abou-Shakra F (2002) Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Rapid Commun.Mass Spectrom 16: 220-228. 
• Mombouli JV, Vanhoutte PM (1995) Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 35: 679-705. 
• Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ (2000) Metabolism of bradykinin in vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther 294: 263-269. 
• Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, Morrow JD (2001) Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal Biochem 292: 87-93. 
• Murphey LJ, Eccles WK, Williams GH, Brown NJ (2004) Loss of sodium modulation of plasma kinins in human hypertension. J Pharmacol Exp Ther 308: 1046-1052. 
• Olszanecki R, Gebska A, Korbut R (2006) Production of prostacyclin and prostaglandin E2 in resting and IL-1beta-stimulated A549, HUVEC and hybrid EA.HY 926 cells. J Physiol Pharmacol 57: 649-660. 
• Olszanecki R, Madej J, Suski M, Gebska A, Bujak-Gizycka B, Korbut R (2009) Angiotensin metabolism in rat stomach wall: prevalence of angiotensin-(1-7) formation. J Physiol Pharmacol 60: 191-196. 
• Parker CW (1972) Radioimmunoassays. Prog Clin Pathol 4: 103-141. 
• Protsenko VA (1979) [Immunochemical approach to studying the body's kallikrein-kinin system]. Patol Fiziol Eksp Ter 5: 73-76. 
• Ramírez-Expósito MJ, Martínez-Martos JM (2008) Hypertension, RAS and gender: what is the role of aminopeptidases? Heart Fail Rev 13: 355-365. 
• Sharma JN (2009) Hypertension and the bradykinin system. Curr Hypertens Rep 11: 178-181. 
• Sivieri DO Jr, Bispo-da-Silva LB, Oliveira EB, Resende AC, Salgado MC (2007) Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries. Hypertension 50: 110-115.

Uwagi

PL

Rekord w opracowaniu.